{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:52:42Z","timestamp":1785768762106,"version":"3.56.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Americas"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lana.2026.101475","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T09:13:44Z","timestamp":1776676424000},"page":"101475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Health care utilization and cost implications of Chile's 2024 nirsevimab strategy for RSV prevention: a counterfactual analysis"],"prefix":"10.1016","volume":"59","author":[{"given":"Denis","family":"Saur\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Zgheib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Goic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Thraves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javiera","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Del Solar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignasi","family":"Neira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"O'Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9097-6266","authenticated-orcid":false,"given":"Leonardo J.","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lana.2026.101475_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiph.2025.102680","article-title":"Cost-savings and health impact of strategies for prevention of respiratory syncytial virus with nirsevimab in Chile based on the integrated analysis of 2019\u201323 national databases: a retrospective study","volume":"18","author":"Saur\u00e9","year":"2025","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.lana.2026.101475_bib2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S1473-3099(25)00233-6","article-title":"Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational study","volume":"25","author":"Torres","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lana.2026.101475_bib3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1473-3099(24)00215-9","article-title":"Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study","volume":"24","author":"Ares-G\u00f3mez","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lana.2026.101475_bib4","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/archdischild-2024-327153","article-title":"Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)","volume":"109","author":"Coma","year":"2024","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.lana.2026.101475_bib5","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2025.30.5.2400596","article-title":"Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case-control study, Spain, 2023\/24 season","volume":"30","author":"N\u00fa\u00f1ez","year":"2025","journal-title":"Euro Surveill"},{"key":"10.1016\/j.lana.2026.101475_bib6","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/INF.0000000000004672","article-title":"Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital care settings: a seasonal cohort study of infants in Catalonia (Spain)","volume":"44","author":"Perramon-Malavez","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.lana.2026.101475_bib7","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S2352-4642(24)00171-8","article-title":"Real-world effectiveness of nirsevimab immunisation against bronchiolitis in infants: a case\u2013control study in Paris, France, 2024","volume":"8","author":"Carbajal","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.lana.2026.101475_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13311","article-title":"Nirsevimab effectiveness against cases of respiratory syncytial virus bronchiolitis hospitalised in paediatric intensive care units in France, September 2023\u2013January 2024","volume":"18","author":"Paireau","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.lana.2026.101475_bib9","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400275","article-title":"Nirsevimab effectiveness at preventing RSV-related hospitalisation in infants","volume":"4","author":"Jabagi","year":"2025","journal-title":"NEJM Evid"},{"key":"10.1016\/j.lana.2026.101475_bib10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.15585\/mmwr.mm7309a4","article-title":"Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus-associated hospitalisation among infants entering their first respiratory syncytial virus season: New Vaccine Surveillance Network, October 2023\u2013February 2024","volume":"73","author":"Moline","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.lana.2026.101475_bib11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jamapediatrics.2024.5572","article-title":"Respiratory syncytial virus disease burden and nirsevimab effectiveness in young children from 2023\u201324","volume":"179","author":"Moline","year":"2024","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.lana.2026.101475_bib12","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.15585\/mmwr.mm7345a1","article-title":"Nirsevimab effectiveness against medically attended respiratory syncytial virus illness and hospitalisation among Alaska Native children: Yukon-Kuskokwim Delta Region, Alaska, October 2023\u2013June 2024","volume":"73","author":"Lefferts","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.lana.2026.101475_bib13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00431-025-06050-7","article-title":"Effectiveness of nirsevimab in reducing hospitalisations in emergency departments due to bronchiolitis among infants under 3 months: a retrospective study","volume":"184","author":"Marouk","year":"2025","journal-title":"Eur J Pediatr"},{"issue":"6","key":"10.1016\/j.lana.2026.101475_bib14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2352-4642(25)00093-8","article-title":"Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis","volume":"9","author":"Sumsuzzman","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"issue":"2","key":"10.1016\/j.lana.2026.101475_bib15","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S1473-3099(24)00811-9","article-title":"Full 2023\u201324 season results of universal prophylaxis with nirsevimab in Galicia, Spain: the NIRSE-GAL study","volume":"25","author":"Mallah","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"21","key":"10.1016\/j.lana.2026.101475_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126164","article-title":"Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants","volume":"42","author":"Gebretekle","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.lana.2026.101475_bib17","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s40121-025-01134-1","article-title":"Cost-effectiveness and public health impact of universal prophylaxis with nirsevimab against respiratory syncytial virus (RSV) infections in all infants in Japan","volume":"14","author":"Noto","year":"2025","journal-title":"Infect Dis Ther"},{"issue":"6","key":"10.1016\/j.lana.2026.101475_bib18","article-title":"Cost-effectiveness of nirsevimab for respiratory syncytial virus in infants and young children","volume":"154","author":"Hutton","year":"2024","journal-title":"Pediatrics"},{"key":"10.1016\/j.lana.2026.101475_bib19","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1080\/01621459.2021.1929245","article-title":"The augmented synthetic control method","volume":"116","author":"Ben-Michael","year":"2021","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.lana.2026.101475_bib20","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1073\/pnas.1612833114","article-title":"Estimating the population-level impact of vaccines using synthetic controls","volume":"114","author":"Bruhn","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.lana.2026.101475_bib21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1198\/jasa.2009.ap08746","article-title":"Synthetic control methods for comparative case studies: estimating the effect of California's tobacco control program","volume":"105","author":"Abadie","year":"2010","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.lana.2026.101475_bib22","series-title":"Balancing, Regression, Difference-in-Differences and Synthetic Control Methods: A Synthesis. NBER Working Paper 22791","author":"Doudchenko","year":"2016"}],"container-title":["The Lancet Regional Health - Americas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X26001055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X26001055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:07:48Z","timestamp":1784095668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667193X26001055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":22,"alternative-id":["S2667193X26001055"],"URL":"https:\/\/doi.org\/10.1016\/j.lana.2026.101475","relation":{},"ISSN":["2667-193X"],"issn-type":[{"value":"2667-193X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health care utilization and cost implications of Chile's 2024 nirsevimab strategy for RSV prevention: a counterfactual analysis","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Americas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lana.2026.101475","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101475"}}